

Hutchison Whampoa Limited

(incorporated in Hong Kong with limited liability)

(Stock Code: 013)

OVERSEAS REGULATORY ANNOUNCEMENT

Please refer to the attached announcement of Hutchison China MediTech Limited, which is listed on the Alternative Investment Market operated by the London Stock Exchange and a 71.6% owned subsidiary of Hutchison Whampoa Limited.

As at the date of the announcement, the Directors of Hutchison Whampoa Limited are:

Executive Directors:

Mr. LI Ka-shing (*Chairman*)
Mr. LI Tzar Kuoi, Victor (*Deputy Chairman*)
Mr. FOK Kin-ning, Canning
Mrs. CHOW WOO Mo Fong, Susan
Mr. Frank John SIXT
Mr. LAI Kai Ming, Dominic
Mr. KAM Hing Lam

Non-executive Directors:

Mr. George Colin MAGNUS
Mr. William SHURNIAK

Independent Non-executive Directors:

The Hon. Sir Michael David KADOORIE
Mr. Holger KLUGE
Mr. William Elkin MOCATTA
*(Alternate to The Hon. Sir Michael
David Kadoorie)*
Mr. OR Ching Fai, Raymond
Mr. WONG Chung Hin

Hong Kong, 9 May 2008



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited (“Chi-Med”)
(AIM: HCM)**

Results of Annual General Meeting

London, Friday, 9 May 2008: Chi-Med today announces that all ordinary resolutions and special resolution put to its Annual General Meeting (“AGM”) held on 9 May 2008 were duly passed. The poll results of the resolutions were as follows:

		Number of Votes (%)*		
Ordinary Resolutions		For	Against	Withheld
1	To consider and adopt the audited financial statements and the reports of the directors and independent auditor for the year ended 31 December 2007.	41,885,390 (100.00%)	0 (0.00%)	0 (0.00%)
2(a)	To re-elect Mr Simon To as a director.	41,735,389 (99.64%)	0 (0.00%)	150,000 (0.36%)
2(b)	To re-elect Mr Christian Salbaing as a director.	41,114,739 (98.16%)	770,651 (1.84%)	0 (0.00%)
2(c)	To re-elect Mr Michael Howell as a director.	41,885,390 (100.00%)	0 (0.00%)	0 (0.00%)
3	To re-appoint PricewaterhouseCoopers as the auditor of the Company and authorise the board of directors to fix the auditor’s remuneration.	41,885,390 (100.00%)	0 (0.00%)	0 (0.00%)
4(a)	Item 4(A) of the notice of the Meeting (To grant a general mandate to the directors of the Company to issue additional shares)	41,885,390 (100.00%)	0 (0.00%)	0 (0.00%)
4(b)	Item 4(B) of the notice of the Meeting (To grant a general mandate to the directors of the Company to repurchase shares of the Company)	41,885,390 (100.00%)	0 (0.00%)	0 (0.00%)
5	Item 5 of the notice of the Meeting (To extend the general mandate to the directors of the Company to issue additional shares)	41,885,390 (100.00%)	0 (0.00%)	0 (0.00%)
Special Resolution				
6	Item 6 of the notice of the Meeting (To amend the Articles of Association of the Company)	41,885,390 (100.00%)	0 (0.00%)	0 (0.00%)

*All percentages rounded to 2 decimal places.

As at the date of the AGM, the number of issued shares of Chi-Med was 51,229,174, which was the total number of shares entitling the holders to attend and vote on the ordinary resolutions and special resolution proposed at the AGM.

Ends

Enquiries

Citigate Dewe Rogerson
Anthony Carlisle
David Dible

Telephone: +44 (0) 20 7638 9571
+44 (0) 7973 611 888
+44 (0) 7967 566 919

About Chi-Med

Chi-Med is the holding company of a pharmaceutical and healthcare group focused on traditional Chinese medicine ("TCM") based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. Chi-Med operates three core business Divisions: 1) China Healthcare – the manufacture, distribution and marketing of pharmaceuticals and health supplements in China; 2) Drug R&D – the discovery and global development of novel drug in the oncology and auto-immune therapeutic areas; and 3) Consumer Products – global retailing and distribution consumer health and personal care products derived from TCM and botanical ingredients.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.